SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

REGN

Regeneron Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

Traders should monitor progress in the radiopharmaceutical pipeline, especially early clinical data readouts. The 50/50 structure enhances Regeneron's long-term revenue potential compared to traditional licensing deals, but also increases R&D spend. Any opt-out by Telix on co-funding would shift the risk to Regeneron but reduce future profit share.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$745.61
T+0 close · Apr 13, 2026 · via day close
Latest settled
−9.30%
T+60 · $676.23
Vs SPY
−18.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $745.61entry
  2. T+1 · 7mo ago +1.29%α +0.08% · $755.25
  3. T+5 · 7mo ago +0.49%α −2.81% · $749.26
  4. T+20 · 6mo ago −4.81%α −12.54% · $709.73
  5. T+60 · 4mo ago −9.30%α −18.28% · $676.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Regeneron paying $40 million upfront for access to four initial programs. The 50/50 cost and profit-sharing model marks Regeneron's strategic entry into radiopharmaceuticals, combining its antibody expertise with Telix’s radiopharmaceutical infrastructure.

Key Financial Metrics

Deal Value
$40.0M

Key Facts

  • Regeneron pays Telix $40 million upfront for four initial radiopharmaceutical programs.
  • Partnership operates under a 50/50 cost and profit-sharing model, with co-development and co-commercialization rights.
  • Telix retains option to opt-out of co-funding and instead receive up to $535 million per program in milestones plus low double-digit royalties.
  • Regeneron gains option to expand the collaboration to four additional programs with further upfront payments.
  • Joint development of radio-diagnostics to support patient selection and treatment monitoring.

Financial Impact

$40 million upfront payment; potential future milestone payments up to $2.1 billion aggregate; 50% shared commercialization costs and profits.

R&D expensefuture revenueprofit sharingdilution

Risk Factors

  • Clinical failure risk in early-stage radiopharmaceutical programs.
  • Potential for Telix to opt-out of co-funding, increasing Regeneron's financial burden.
  • Regulatory delays in novel radiopharmaceutical approvals.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272314

Track record

53 reports on REGN

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026